Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Novo Nordisk's new CEO, Mike Doustdar, is considering layoffs as part of cost-saving measures. He aims to review all company expenses, including salaries, but assures a fair process. Doustdar, a ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo Nordisk on Tuesday appointed insider Mike Doustdar as its new chief executive after the Danish obesity drug maker cut its full year outlook for the second time in 2025, sending its shares ...

Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales growth and sliding share price. He first will need to win over sceptical ...

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

Novo Nordisk shares climbed in premarket trading Monday after the U.S. Food and Drug Administration granted accelerated ...

The GLP-1 weight-loss drug giant just cut its investor guidance for 2025. Could the boom be over? Health-related stocks are not having a good day. First, America’s largest health insurance provider, ...

Danish leader will face a challenging landscape among competitors ...

Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new president and chief executive officer (CEO).